Cargando…
Sodium-glucose co-transporter 2 inhibitors beyond diabetes
Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease. Th...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
NPS MedicineWise
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427625/ https://www.ncbi.nlm.nih.gov/pubmed/36110166 http://dx.doi.org/10.18773/austprescr.2022.036 |